Biotron Ltd BITRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.06–0.06
- 52-Week Range
- $0.00–0.08
- Bid/Ask
- $0.03 / $0.09
- Market Cap
- $52.78 Mil
- Volume/Avg
- 5,000 / 13,928
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.biotron.com.au
Valuation
|
Metric
|
BITRF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 41.46 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BITRF
|
|---|---|
Quick Ratio | 1.15 |
Current Ratio | 3.85 |
Interest Coverage | — |
Quick Ratio
BITRF
Profitability
|
Metric
|
BITRF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BITRF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cmrhxshhhq | Crsk | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fwtzlknr | Yjrqbs | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nltltnpv | Wjxdmyp | $103.7 Bil | |
MRNA
| Moderna Inc | Qcglbcf | Srdt | $47.9 Bil | |
ARGX
| argenx SE ADR | Cgmzvgkc | Gdmsn | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Mnhrkljw | Qngrd | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kjxdchzx | Fwwcp | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rfnlrvzw | Czmpzk | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vpkxbfcrt | Vplkwc | $12.8 Bil | |
INCY
| Incyte Corp | Rfnmrdx | Zvhqnzy | $12.1 Bil |